Scholarlink

<p>Obesity is a major public health concern linked to increased morbidity and mortality. Bariatric surgery, particularly sleeve gastrectomy (SG), is an effective treatment for morbid obesity, facilitating significant weight loss and metabolic improvements. This study investigated changes in serum asprosin and fibroblast growth factor-21 (FGF-21) levels following SG and their potential associations with weight loss and glycemic parameters. Fifty obese patients from the Antalya Training and Research Hospital Obesity Solution Center were included based on NIH and ASMBS guidelines, with exclusions for prior bariatric surgery, severe organ failure, or uncontrolled psychiatric disorders. Due to follow-up limitations, 33 patients completed the study. At the 12-month follow-up, significant reductions were observed in weight (− 40.3 ± 15.39&#xa0;kg), BMI (− 15.58 ± 5.32&#xa0;kg/m<sup>2</sup>), waist circumference (− 34.79 ± 12.02&#xa0;cm), and arm circumference (− 5.85 ± 4.01&#xa0;cm) (<i>p</i> &lt; 0.001). Serum asprosin levels decreased from 21.32 (17.73–37.23) to 13.56 (10.46–27.43) (<i>p</i> &lt; 0.001), and FGF-21 levels decreased from 260.73 (220.25–457.57) to 192.33 (137.88–306.1) (<i>p</i> &lt; 0.001). Significant reductions were also observed in HbA1c [6 (5.5–7.8) to 5.2 (5.1–5.7)] and fasting glucose [110 (93–166) to 91 (84–106)] (<i>p</i> &lt; 0.001). No significant correlations were found between changes in asprosin and FGF-21 levels and other clinical parameters. Comparisons with controls showed higher baseline asprosin and FGF-21 levels in the control group (<i>p</i> &lt; 0.001 and <i>p</i> = 0.005, respectively). SG significantly reduced asprosin and FGF-21 levels, likely due to weight and fat loss, though their roles in glycemic control remain unclear. Further research is needed to elucidate their metabolic functions in obesity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of Asprosin and FGF21 on Weight Loss and Glucose Metabolism Following Sleeve Gastrectomy

  • 期刊论文

  • 发表日期：

    2025年4月25日

查看全文
  • Alper Seydican Türker,
  • Umut Rıza Gündüz,
  • Güzin Aykal,
  • Aydın Dincer,
  • Hasan Özkan,
  • Ömer Çelik,
  • Muhammed Ali Aydın

摘要

Obesity is a major public health concern linked to increased morbidity and mortality. Bariatric surgery, particularly sleeve gastrectomy (SG), is an effective treatment for morbid obesity, facilitating significant weight loss and metabolic improvements. This study investigated changes in serum asprosin and fibroblast growth factor-21 (FGF-21) levels following SG and their potential associations with weight loss and glycemic parameters. Fifty obese patients from the Antalya Training and Research Hospital Obesity Solution Center were included based on NIH and ASMBS guidelines, with exclusions for prior bariatric surgery, severe organ failure, or uncontrolled psychiatric disorders. Due to follow-up limitations, 33 patients completed the study. At the 12-month follow-up, significant reductions were observed in weight (− 40.3 ± 15.39 kg), BMI (− 15.58 ± 5.32 kg/m2), waist circumference (− 34.79 ± 12.02 cm), and arm circumference (− 5.85 ± 4.01 cm) (p < 0.001). Serum asprosin levels decreased from 21.32 (17.73–37.23) to 13.56 (10.46–27.43) (p < 0.001), and FGF-21 levels decreased from 260.73 (220.25–457.57) to 192.33 (137.88–306.1) (p < 0.001). Significant reductions were also observed in HbA1c [6 (5.5–7.8) to 5.2 (5.1–5.7)] and fasting glucose [110 (93–166) to 91 (84–106)] (p < 0.001). No significant correlations were found between changes in asprosin and FGF-21 levels and other clinical parameters. Comparisons with controls showed higher baseline asprosin and FGF-21 levels in the control group (p < 0.001 and p = 0.005, respectively). SG significantly reduced asprosin and FGF-21 levels, likely due to weight and fat loss, though their roles in glycemic control remain unclear. Further research is needed to elucidate their metabolic functions in obesity.